SG11202001460TA - Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt - Google Patents

Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt

Info

Publication number
SG11202001460TA
SG11202001460TA SG11202001460TA SG11202001460TA SG11202001460TA SG 11202001460T A SG11202001460T A SG 11202001460TA SG 11202001460T A SG11202001460T A SG 11202001460TA SG 11202001460T A SG11202001460T A SG 11202001460TA SG 11202001460T A SG11202001460T A SG 11202001460TA
Authority
SG
Singapore
Prior art keywords
telmisartan
formulation
pharmaceutically acceptable
acceptable salt
dissolution rate
Prior art date
Application number
SG11202001460TA
Inventor
Dong Jin Lee
Min Kwan Cho
Shin Jung Park
Jong Lae Lim
Original Assignee
Chong Kun Dang Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66539176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11202001460T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chong Kun Dang Pharmaceutical Corp filed Critical Chong Kun Dang Pharmaceutical Corp
Publication of SG11202001460TA publication Critical patent/SG11202001460TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11202001460TA 2017-11-15 2018-10-16 Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt SG11202001460TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170152226A KR102066832B1 (en) 2017-11-15 2017-11-15 Formulation having improved madescent and dissolution rate comprising Telmisartan or its pharmaceutically acceptable salt
PCT/KR2018/012191 WO2019098540A1 (en) 2017-11-15 2018-10-16 Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt

Publications (1)

Publication Number Publication Date
SG11202001460TA true SG11202001460TA (en) 2020-03-30

Family

ID=66539176

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202001460TA SG11202001460TA (en) 2017-11-15 2018-10-16 Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt

Country Status (6)

Country Link
KR (1) KR102066832B1 (en)
MY (1) MY196892A (en)
PH (1) PH12020550597A1 (en)
SG (1) SG11202001460TA (en)
TW (2) TWI734046B (en)
WO (1) WO2019098540A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101010325B1 (en) * 2009-12-17 2011-01-25 현대약품 주식회사 Pharmaceutical composition comprising telmisartan and hydrochlorothiazide
WO2011149438A1 (en) * 2010-05-28 2011-12-01 Mahmut Bilgic Combination of antihypertensive agents
KR20150111686A (en) * 2014-03-26 2015-10-06 주식회사 종근당 Pharmaceutical Preparation Comprising Telmisartan and (S)-Amlodipine with Improved Oxidative Stability.
KR101750689B1 (en) * 2015-09-15 2017-06-26 주식회사 종근당 Pharmaceutical combination preparation
KR101823071B1 (en) * 2016-02-15 2018-01-29 한림제약(주) Process for preparing telmisartan-containing tablets

Also Published As

Publication number Publication date
KR20190055471A (en) 2019-05-23
PH12020550597A1 (en) 2021-02-15
TW201922242A (en) 2019-06-16
WO2019098540A1 (en) 2019-05-23
KR102066832B1 (en) 2020-01-16
TW202026000A (en) 2020-07-16
TWI734046B (en) 2021-07-21
MY196892A (en) 2023-05-09

Similar Documents

Publication Publication Date Title
IL256085B (en) A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment
ZA201906451B (en) 4-pyridone compound or salt thereof, and pharmaceutical composition and formulation including same
IL257481B (en) Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof
HK1249103B (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
GB201709141D0 (en) Pharmaceutical formulation
IL255823A (en) Urea derivative or pharmacologically acceptable salt thereof
HK1256674A1 (en) Deuterium-modified brigatinib derivatives, pharmaceutical compositions comprising same, and use thereof
IL273339A (en) Griseofulvin compound and pharmaceutical use thereof
IL256339A (en) Pyrazole derivative or pharmaceutically acceptable salt thereof
EP2987786A4 (en) Amidopyridinol derivative or pharmaceutically acceptable salt thereof and pharmaceutical composition comprising same as active component
ZA201704743B (en) Mangiferin-6-o-berberine salt and preparation method and use thereof
PL3658122T3 (en) Pharmaceutical composition comprising sacubitril and valsartan
IL280389A (en) A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment
IL250713A0 (en) A pesticide formulation comprising a water soluble active ingredient and a penetration enhancer and use of the same
IL271673A (en) Enhanced solubility drug-containing formulations
IL269884B1 (en) Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor
SI3349594T1 (en) Salt substitute composition and use thereof
HUE056301T2 (en) Salt of substituted urea derivative and use thereof in medicine
HK1243351A1 (en) Pharmaceutical composition comprising pyridopyrimidine derivative or pharmaceutically acceptable salt thereof
IL254711B (en) Diazepino-indole derivatives and pharmaceutical compositions comprising it
SG11202001460TA (en) Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt
ZA202000959B (en) Adamantylmethylamine derivative and use thereof as pharmaceutical
SI3778609T1 (en) Penam derivatives or salts thereof, pharmaceutical compositions and use thereof
SG11201700122TA (en) Pharmaceutical compound comprising 13 glycerides, formulation and application thereof
EP3604291A4 (en) Compound or salt thereof, antiviral agent, and pharmaceutical composition